Finally, we evaluated the clinical relevance of SNAI2 expression in metastatic lesions from two independent cohorts of patients with ER+ breast cancer treated with endocrine therapy in the advanced setting and showed that high SNAI2 levels correlated significantly with shorter PFS in patients on endocrine therapy, including fulvestrant. This evidence concerns the gene ESR1 and breast carcinoma.